Actively Recruiting
SMC Radiation Oncology SABR Cohort for Oligometastasis
Led by Samsung Medical Center · Updated on 2025-08-13
60
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
CONDITIONS
Official Title
SMC Radiation Oncology SABR Cohort for Oligometastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Performance status (ECOG PS) of 0 to 2
- Diagnosed with metastatic disease
- Confirmed oligometastatic or oligoprogressive cancer with up to 5 lesions on imaging within 4 weeks
You will not qualify if you...
- Previous radiotherapy to the site planned for SABR
- Presence of brain metastases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung medical center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
N
Nalee Kim, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here